Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Delisting

The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four years after being founded.

With no cure in sight, drugs firm LianBio begins exit strategy

The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four…
February 23, 2024
LIAN.US

Former aluminum highflyer Zhongwang headed for listed company scrapheap  

The company will be booted from the Hong Kong Stock Exchange on Thursday after failing to provide any financials since its 2020 annual report Key Takeaways: Zhongwang will be de-listed…
April 11, 2023

Tuya Seeks Hong Kong IPO to Hedge U.S. Delisting Risk, But Investors Are Wary

With the possibility of being forced to delist from the U.S. market by the SEC, Tuya is primarily seeking a safe harbor and only aims to raise a conservative HK$140…
June 28, 2022

Investors Unfazed as TAL Education Added to List of Chinese Firms at Risk of Delisting

The education company’s shares fell 1.6% after it was cited by the U.S. securities regulator for non-compliance with the Holding Foreign Companies Accountable Act Key Takeaways: The U.S. Securities and…
June 28, 2022

FAST NEWS: Hutchmed Receives Additional Holdings from U.S. Fund

The latest: The Capital Group Companies, Inc., a U.S.-based fund disclosed it purchased 1.285 million shares in Hutchmed (China) Ltd. (HCM.US; 0013.HK) for HK$22.14 million ($2.84 million), raising its stake…
June 15, 2022

FAST NEWS: Luckin Coffee Denies Hong Kong Listing Plan

The latest: Chinese coffee chain Luckin Coffee Inc. (LKNCY.US) said in a statement Monday that it is not seeking a Hong Kong listing at this time, refuting a media report…
May 11, 2022

FAST NEWS: Qudian Regains Compliance With New York Listing Rules

The latest: Online lender Qudian Inc. (QD.US) said on Thursday it has regained compliance with New York Stock Exchange listing rules, after its average closing price for the last 30…
May 6, 2022
Load more

Recent Articles

The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four years after being founded.
February 23, 2024

With no cure in sight, drugs firm LianBio begins exit strategy

LIAN.US
April 11, 2023

Former aluminum highflyer Zhongwang headed for listed company scrapheap  

June 28, 2022

Tuya Seeks Hong Kong IPO to Hedge U.S. Delisting Risk, But Investors Are Wary

June 28, 2022

Investors Unfazed as TAL Education Added to List of Chinese Firms at Risk of Delisting

June 15, 2022

FAST NEWS: Hutchmed Receives Additional Holdings from U.S. Fund

May 11, 2022

FAST NEWS: Luckin Coffee Denies Hong Kong Listing Plan

May 6, 2022

FAST NEWS: Qudian Regains Compliance With New York Listing Rules

RECENT ARTICLES

  1. 派格生物減肥藥
    November 21, 2024
    PegBio aims to bulk up its finances to deliver weight-loss drugs
  2. December 2, 2024
    Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  3. March 20, 2025
    A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  4. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  5. March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  6. January 24, 2025
    BeiGene heads for profit milestone after hemorrhaging cash
    6160.HK ONC.US 688235.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.